CA2167393A1 - Noninvasive glucose monitor - Google Patents
Noninvasive glucose monitorInfo
- Publication number
- CA2167393A1 CA2167393A1 CA 2167393 CA2167393A CA2167393A1 CA 2167393 A1 CA2167393 A1 CA 2167393A1 CA 2167393 CA2167393 CA 2167393 CA 2167393 A CA2167393 A CA 2167393A CA 2167393 A1 CA2167393 A1 CA 2167393A1
- Authority
- CA
- Canada
- Prior art keywords
- glucose
- patient
- collection medium
- skin
- reservoir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 125
- 239000008103 glucose Substances 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 claims abstract description 35
- 239000008280 blood Substances 0.000 claims abstract description 17
- 210000004369 blood Anatomy 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000012544 monitoring process Methods 0.000 claims abstract description 11
- 210000004243 sweat Anatomy 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 10
- 239000000411 inducer Substances 0.000 claims description 9
- 230000035699 permeability Effects 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 6
- 108090000790 Enzymes Proteins 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 4
- 230000008020 evaporation Effects 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 10
- 210000003722 extracellular fluid Anatomy 0.000 abstract description 8
- 210000000434 stratum corneum Anatomy 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 230000005611 electricity Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000004832 voltammetry Methods 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 210000004955 epithelial membrane Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229910002835 Pt–Ir Inorganic materials 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
This invention is a noninvasive glucose moni-toring apparatus and method that does not rely upon heat, electricity or chemicals to collect glucose from interstitial fluid across the patient's skin. Moreover, the method and apparatus monitor blood glucose in real time, i.e., in a time period short enough to enable a diabetic to take appropriate action to correct blood glucose levels. A collection device (10) comprising a reservoir (12) containing a glucose collection medium such as water is placed against the stratum corneum of the patient's skin for a predetermined period of time.
At least a portion of the glucose collection medium is removed from the reservoir at the end of the predeter-mined time and analyzed for glucose concentration.
At least a portion of the glucose collection medium is removed from the reservoir at the end of the predeter-mined time and analyzed for glucose concentration.
Description
~ 095/02357 2 1 6 7 3 9~ PCT~S94/06684 NONINVASIVE GLUCOSE MONITOR
Bac~y ouud of the Invention This invention relates generally to methods and apparatus for glucose collection and concentration measurement. In particular, the invention is directed to a method and apparatus for monitoring blood glucose levels noninvasively through a patient's skin.
People suffering from diabetes mellitus must monitor blood glucose levels over the course of the day.
The most common prior art method of measuring blood glucose levels is by actually drawing a portion of the subject's blood and performing a chemical analysis on the sample. Continually drawing blood creates safety risks for the patient, however, The prior art has described "non~nvasive"
methods for measuring blood glucose levels. These supposedly noninvasive methods actually involve the application of chemicals, electricity, heat, or negative pressure to draw out body fluids other than blood that may nonetheless contain levels of glucose that correlate with blood glucose levels. For example, U.S. Patent No.
5,161,532 describes a glucose sensor that uses a pump to draw interstitial fluid out through the patient's skin into a sensor. The '532 patent states that any glucose in the interstitial fluid reacts with a chemical within the sensor to produce an electrical signal that is detected by a pair of electrodes.
U.S. Patent No. 5,036,861 describes a glucose monitor that collects the patient's sweat through a skin patch attached to the patient's wrist. Iontophoresis is W095/023~7 2 ~ ~ 7 ~ ` PCT~S94/06684 used to transdermally introduce a gel into the patient's skin. The gel contains a cholinergic agent for stimulating the secretion mechanism o~ the eccrine sweat gland and agents that m;n;m;ze or prevent loss of glucose from the sweat as it travels from the sweat gland to the skin patch. As in the '532 patent, the device described in the '861 patent measures the glucose level in the collected sweat using electrodes.
U.S. Patent No. 5,139,023 describes yet another "noninvasive" apparatus and method for monitoring blood glucose. The monitor includes a glucose receiving medium such as water enclosed in a housing that holds the receiving medium against the patient's epithelial membrane. The glucose receiving medium includes a permeation enhancing chemical such as a natural bile salt that enhances glucose p~rm~hility from interstitial fluid across the epithelial membrane into the monitor.
An attempt to collect glucose according to the '023 method and apparatus but without any permeation enhancing agent failed to show that any glucose was collected.
Finally, publish'ed European Patent Application EP 0 304 304 discloses a trans~rm~l glucose detection system in which the detector contains a porous carrier saturated with detector chemicals. The detector adhesively attaches to the patient's skin. A membrane serves as a barrier to prevent migration of the detector chemicals out of the detector while permitting glucose to migrate into the detector. Interaction between glucose and the detector chemicals causes a perceivable color change over a six to twelve hour period. The device only detects the presence of glucose; it does not measure the actual amount of glucose in the detector.
-O95/02357 ~ 9 3 PCT~S94/06684 Summary of the Invention This invention provides a truly noninvasive glucose monitoring apparatus and method that does not rely upon heat, electricity or chemicals to collect glucose from interstitial fluid across the patient~s skin. Moreover, the method and apparatus of this invention monitor blood glucose in real time, that is to say, in a time period short enough to enable a diabetic to take appropriate action to correct blood glucose levels.
In a preferred embodiment, a collection device comprising a reservoir cont~in;ng a glucose collection medium such as water is placed against the stratum corneum of the patient's skin for a predetermined period of time. At least a portion of the glucose collection medium is removed from the reservoir at the end of the predetermined time and analyzed for glucose concentration.
Brief Descrlption of the Drawings Figure 1 is a side cross-sectional view of a glucose collection device according to the preferred embodiment of this invention.
Figure 2 is a bottom elevational view of the preferred glucose collection device.
Figure 3 is a cross-sectional view of a sensor for use with a glucose analysis method for use with this in~ention.
Figure 4 is a schematic representation of a glucose monitoring system according to this invention.
Detailed Description of the Preferred Rmhodiment This invention presents a simple and noninvasive method for monitoring blood glucose levels.
It is well-known that glucose can be found in a patient's , wog5/0~57 ~ 9 3 PCT~S94/06684 -interstitial fluid and in a patient's sweat. Heretofore, however, it had been thought that glucose could not cross the patient's skin in a detectable amount in real time without the use of a permeability enhancer. See, e.g., U.S. Patent No. 5,139,023 at col. 7, line 3. It had also been thought that even when sweat or interstitial fluid is actively extracted from the patient, active ph~rm~cological agents are needed to preserve the presence of glucose in the extracted sample. See, e.g., U.S. Patent No. 5,036,861, col. 3, lines 1-10.
This invention is a method and apparatus for detecting blood glucose in a truly noninvasive manner without actively extracting interstitial fluid from the patient and without the use of sweat inducers, glucose preservers or p~rm~hility enhancers. In a preferred embo~;m~nt, glucose is collected through the stratum corneum of the patient's skin by a reservoir cont~;n;ng a glucose collection medium. After the passage of a predeterm;n~ time period, the glucose collection medium is analyzed to measure the quantity of gluco~e present.
A preferred collection device for practicing this invention is shown in Figures 1 and 2. The device 10 comprises a reservoir 12 bordered by a cover 14, adhesive layer 16, and the stratum corneum of the patient's skin 18. As shown in part in Figure 2, the device is formed by attaching the plastic cover 14 to a double-sided adhesive 16 in which an oval or other-~haped hole has been formed. In the preferred embodiment, cover 14 is formed from cellophane plastic and adhesive layer 16 is Avery double-sided adhesive, part no. MED 3044.
The preferred glucose collection medium is distilled deionized water. According to the preferred method, the distilled deionized water is injected into reservoir 12 through a hypo~rm;c needle and syringe 20.
Despite suggestions to the contrary in the prior art, 2 t ~ ~ ~ 9 ~ PCT~S94/06684 glucose will migrate from the patient's interstitial fluid through the skin 18 and into the water within reservoir 12. After the water has rested against the patient's skin for a predetermined period of time, the water is withdrawn for analysis. This glucose collection device and method can collect glucose from the patient without the use of chemicals or mechanical extraction.
Alternatively, a hydrogel may be used as a collection medium. Suitable hydrogels are described in U.S. Patent No. 5,139,023.
Water (or other collection medium) from the reservoir may be extracted at periodic intervals (preferably in the range of 5 to 10 minutes) and analyzed to determine its glucose content. A preferred glucose analysis method is described by LaCourse et al. in "Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry,"
65 Analytical Chemistry 50-55 (1 January 1993), although other analysis methods may be used. The preferred pulse amperometric voltammetry (PAD) analysis method combines high performance liquid chromatography with electrochemical detection using bi-directional voltage waveforms. Specifically, water extracted from the reservoir is diffused onto a chromatography column. The column is washed with a high pressure solvent such as a NaOH solution. A stepped voltage waveform is applied across two electrodes in the solution, one of which is a gold rotating disk electrode. The voltage waveform has three parts: a detection potential in the range of -200 to +400 mV for greater than 40 ms detection period, an oxidation potential in the range of 300 to 800 mV for greater than approximately 60 ms, and a reduction potential in the range of -800 to +100 mV for greater than approximately 60 ms. A plot of electrode current at the gold electrode versus applied voltage yields a curve W095/02357 2 ~ 6 7 3 ~ ~ PCT~S94/06684 ~
with signature peaks at specific voltage values for certain solutes such as glucose. The peak amplitude or peak area are measures of the concentration o~ that solute .
An alternative glucose concentration analysis method is shown schematically in Figures 3 and 4. The glucose measurement technique of this embodiment is similar to the enzymatic technique described in U.S.
Patent No. 5,165,407 and does not require the glucose collection medium to be extracted from the collection device.
A glucose sensor 30 is shown in detail in Figure 3. A sensor body 32 is received within a stainless steel hollow tubular needle 34. The sensor body includes a Teflon-coated platinum-iridium wire 36 (90~ Pt/10~ Ir) having a total O.D. of about 0.2 mm and a cavity 38 formed therein. Cavity 38 is approximately 1.0 mm in length and is located about 3.0 mm from the distal tip of the wire 36. A glucose oxidase layer 40 is immobilized within the cavity 38, and comprises a cellulose acetate polymer layer attached to the urface of the Pt-Ir wire, with glucose oxidase crosslinked through glutaraldehyde onto the cellulose acetate to form an indicating electrode. The procedure i8 described in more detail in U.S. Patent No. 5,165,407. The entirety of the indicating electrode is covered by a membrane 42 of polyurethane, also as described in U.S. Patent No.
5,165,407, to control the diffusion rate of glucose onto the indicating electrode.
Needle 34 has an aperture 44 adjacent its sharpened distal end 46 to expose layer 40. A silicone rubber plug 48 closes one end of the needle and a bead of epoxy 50 closes the other end, as shown. A plastic sheet 52 surrounding the prs~;mAl end of the needle serves as a holder.
~0 9S/0~57 ~ ` 3 PCT~S94/06684 Figure 4 is a schematic representation of a glucose collection and measurement system using this alternative glucose analysis method. The sensor 30 described above with reference to Figure 3 is inserted into a glucose collection device attached to the patient's skin 18 as described with reference to Figures 1 and 2 above so that the sensor's aperture 44 is exposed to the glucose collection medium 12. A conductor 60 leads from the indicating electrode of sensor 30 to a glucose measurement instrument 62. A second conductor 64 leads from a reference electrode 66 attached to the patient's skin 18. Instrument 62 applies a voltage across conductors 60 and 64; the current measured across the electrodes is related to the concentration of glucose in the collection medium in a manner known in the art.
The invention may be further explained through ~ the following examples. The examples are not intended as a limitation to any claimed embodiment.
Example~ 1-5 Glucose was collected from an adult hllm~n using an apparatus substantially similar to the apparatus shown in Figures 1 and 2. The device was attached to the stratum corneum of the skin on the patient's forearm, and the device's reservoir was initially filled with a sample consisting of 0.5 ml. of distilled deionized water via a hypodermic needle and syringe. The sample was withdrawn from the reservoir after five minutes and was replaced with a fresh sample of distilled deionized water at five minute intervals for a total of 30 minutes. The final sample r~m~; n~ in the reservoir for 30 minutes before being withdrawn and analyzed.
The withdrawn samples were analyzed using pulsed amperometric voltammetry. The results are shown wo gs/02357 2 1 6 ~ 3 ~ 3 PCT/US94/06684 in Table I, with the glucose concentrations expressed in micromoles.
TABLE I
5¦ Sample 1 ¦2 ¦ 3 ¦4 ¦5 0-5 min3.13~M 2.86~M 6.10~M 9.24,1lM 1.66~M
5-10 min 1.74 " 1.42 " 3.80 " 4.07 " 1.05 "
10-15 min 1.08 " 0.85 " 2.53 n 2.90 " 0.83 "
15-20 min 1.44 " 0.88 " 1.67 " 2.24 " 0.56 "
20-25 min 1.13 " 0.46 " 1.48 " 2.57 " 0.70 "
25-30 min 0.77 " 0.56 " 1.15 " 3.07 " 1.09 "
1530-60 min 1.91 " 1.46 " 3.35 " 13.5 " 1.20 "
Bac~y ouud of the Invention This invention relates generally to methods and apparatus for glucose collection and concentration measurement. In particular, the invention is directed to a method and apparatus for monitoring blood glucose levels noninvasively through a patient's skin.
People suffering from diabetes mellitus must monitor blood glucose levels over the course of the day.
The most common prior art method of measuring blood glucose levels is by actually drawing a portion of the subject's blood and performing a chemical analysis on the sample. Continually drawing blood creates safety risks for the patient, however, The prior art has described "non~nvasive"
methods for measuring blood glucose levels. These supposedly noninvasive methods actually involve the application of chemicals, electricity, heat, or negative pressure to draw out body fluids other than blood that may nonetheless contain levels of glucose that correlate with blood glucose levels. For example, U.S. Patent No.
5,161,532 describes a glucose sensor that uses a pump to draw interstitial fluid out through the patient's skin into a sensor. The '532 patent states that any glucose in the interstitial fluid reacts with a chemical within the sensor to produce an electrical signal that is detected by a pair of electrodes.
U.S. Patent No. 5,036,861 describes a glucose monitor that collects the patient's sweat through a skin patch attached to the patient's wrist. Iontophoresis is W095/023~7 2 ~ ~ 7 ~ ` PCT~S94/06684 used to transdermally introduce a gel into the patient's skin. The gel contains a cholinergic agent for stimulating the secretion mechanism o~ the eccrine sweat gland and agents that m;n;m;ze or prevent loss of glucose from the sweat as it travels from the sweat gland to the skin patch. As in the '532 patent, the device described in the '861 patent measures the glucose level in the collected sweat using electrodes.
U.S. Patent No. 5,139,023 describes yet another "noninvasive" apparatus and method for monitoring blood glucose. The monitor includes a glucose receiving medium such as water enclosed in a housing that holds the receiving medium against the patient's epithelial membrane. The glucose receiving medium includes a permeation enhancing chemical such as a natural bile salt that enhances glucose p~rm~hility from interstitial fluid across the epithelial membrane into the monitor.
An attempt to collect glucose according to the '023 method and apparatus but without any permeation enhancing agent failed to show that any glucose was collected.
Finally, publish'ed European Patent Application EP 0 304 304 discloses a trans~rm~l glucose detection system in which the detector contains a porous carrier saturated with detector chemicals. The detector adhesively attaches to the patient's skin. A membrane serves as a barrier to prevent migration of the detector chemicals out of the detector while permitting glucose to migrate into the detector. Interaction between glucose and the detector chemicals causes a perceivable color change over a six to twelve hour period. The device only detects the presence of glucose; it does not measure the actual amount of glucose in the detector.
-O95/02357 ~ 9 3 PCT~S94/06684 Summary of the Invention This invention provides a truly noninvasive glucose monitoring apparatus and method that does not rely upon heat, electricity or chemicals to collect glucose from interstitial fluid across the patient~s skin. Moreover, the method and apparatus of this invention monitor blood glucose in real time, that is to say, in a time period short enough to enable a diabetic to take appropriate action to correct blood glucose levels.
In a preferred embodiment, a collection device comprising a reservoir cont~in;ng a glucose collection medium such as water is placed against the stratum corneum of the patient's skin for a predetermined period of time. At least a portion of the glucose collection medium is removed from the reservoir at the end of the predetermined time and analyzed for glucose concentration.
Brief Descrlption of the Drawings Figure 1 is a side cross-sectional view of a glucose collection device according to the preferred embodiment of this invention.
Figure 2 is a bottom elevational view of the preferred glucose collection device.
Figure 3 is a cross-sectional view of a sensor for use with a glucose analysis method for use with this in~ention.
Figure 4 is a schematic representation of a glucose monitoring system according to this invention.
Detailed Description of the Preferred Rmhodiment This invention presents a simple and noninvasive method for monitoring blood glucose levels.
It is well-known that glucose can be found in a patient's , wog5/0~57 ~ 9 3 PCT~S94/06684 -interstitial fluid and in a patient's sweat. Heretofore, however, it had been thought that glucose could not cross the patient's skin in a detectable amount in real time without the use of a permeability enhancer. See, e.g., U.S. Patent No. 5,139,023 at col. 7, line 3. It had also been thought that even when sweat or interstitial fluid is actively extracted from the patient, active ph~rm~cological agents are needed to preserve the presence of glucose in the extracted sample. See, e.g., U.S. Patent No. 5,036,861, col. 3, lines 1-10.
This invention is a method and apparatus for detecting blood glucose in a truly noninvasive manner without actively extracting interstitial fluid from the patient and without the use of sweat inducers, glucose preservers or p~rm~hility enhancers. In a preferred embo~;m~nt, glucose is collected through the stratum corneum of the patient's skin by a reservoir cont~;n;ng a glucose collection medium. After the passage of a predeterm;n~ time period, the glucose collection medium is analyzed to measure the quantity of gluco~e present.
A preferred collection device for practicing this invention is shown in Figures 1 and 2. The device 10 comprises a reservoir 12 bordered by a cover 14, adhesive layer 16, and the stratum corneum of the patient's skin 18. As shown in part in Figure 2, the device is formed by attaching the plastic cover 14 to a double-sided adhesive 16 in which an oval or other-~haped hole has been formed. In the preferred embodiment, cover 14 is formed from cellophane plastic and adhesive layer 16 is Avery double-sided adhesive, part no. MED 3044.
The preferred glucose collection medium is distilled deionized water. According to the preferred method, the distilled deionized water is injected into reservoir 12 through a hypo~rm;c needle and syringe 20.
Despite suggestions to the contrary in the prior art, 2 t ~ ~ ~ 9 ~ PCT~S94/06684 glucose will migrate from the patient's interstitial fluid through the skin 18 and into the water within reservoir 12. After the water has rested against the patient's skin for a predetermined period of time, the water is withdrawn for analysis. This glucose collection device and method can collect glucose from the patient without the use of chemicals or mechanical extraction.
Alternatively, a hydrogel may be used as a collection medium. Suitable hydrogels are described in U.S. Patent No. 5,139,023.
Water (or other collection medium) from the reservoir may be extracted at periodic intervals (preferably in the range of 5 to 10 minutes) and analyzed to determine its glucose content. A preferred glucose analysis method is described by LaCourse et al. in "Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry,"
65 Analytical Chemistry 50-55 (1 January 1993), although other analysis methods may be used. The preferred pulse amperometric voltammetry (PAD) analysis method combines high performance liquid chromatography with electrochemical detection using bi-directional voltage waveforms. Specifically, water extracted from the reservoir is diffused onto a chromatography column. The column is washed with a high pressure solvent such as a NaOH solution. A stepped voltage waveform is applied across two electrodes in the solution, one of which is a gold rotating disk electrode. The voltage waveform has three parts: a detection potential in the range of -200 to +400 mV for greater than 40 ms detection period, an oxidation potential in the range of 300 to 800 mV for greater than approximately 60 ms, and a reduction potential in the range of -800 to +100 mV for greater than approximately 60 ms. A plot of electrode current at the gold electrode versus applied voltage yields a curve W095/02357 2 ~ 6 7 3 ~ ~ PCT~S94/06684 ~
with signature peaks at specific voltage values for certain solutes such as glucose. The peak amplitude or peak area are measures of the concentration o~ that solute .
An alternative glucose concentration analysis method is shown schematically in Figures 3 and 4. The glucose measurement technique of this embodiment is similar to the enzymatic technique described in U.S.
Patent No. 5,165,407 and does not require the glucose collection medium to be extracted from the collection device.
A glucose sensor 30 is shown in detail in Figure 3. A sensor body 32 is received within a stainless steel hollow tubular needle 34. The sensor body includes a Teflon-coated platinum-iridium wire 36 (90~ Pt/10~ Ir) having a total O.D. of about 0.2 mm and a cavity 38 formed therein. Cavity 38 is approximately 1.0 mm in length and is located about 3.0 mm from the distal tip of the wire 36. A glucose oxidase layer 40 is immobilized within the cavity 38, and comprises a cellulose acetate polymer layer attached to the urface of the Pt-Ir wire, with glucose oxidase crosslinked through glutaraldehyde onto the cellulose acetate to form an indicating electrode. The procedure i8 described in more detail in U.S. Patent No. 5,165,407. The entirety of the indicating electrode is covered by a membrane 42 of polyurethane, also as described in U.S. Patent No.
5,165,407, to control the diffusion rate of glucose onto the indicating electrode.
Needle 34 has an aperture 44 adjacent its sharpened distal end 46 to expose layer 40. A silicone rubber plug 48 closes one end of the needle and a bead of epoxy 50 closes the other end, as shown. A plastic sheet 52 surrounding the prs~;mAl end of the needle serves as a holder.
~0 9S/0~57 ~ ` 3 PCT~S94/06684 Figure 4 is a schematic representation of a glucose collection and measurement system using this alternative glucose analysis method. The sensor 30 described above with reference to Figure 3 is inserted into a glucose collection device attached to the patient's skin 18 as described with reference to Figures 1 and 2 above so that the sensor's aperture 44 is exposed to the glucose collection medium 12. A conductor 60 leads from the indicating electrode of sensor 30 to a glucose measurement instrument 62. A second conductor 64 leads from a reference electrode 66 attached to the patient's skin 18. Instrument 62 applies a voltage across conductors 60 and 64; the current measured across the electrodes is related to the concentration of glucose in the collection medium in a manner known in the art.
The invention may be further explained through ~ the following examples. The examples are not intended as a limitation to any claimed embodiment.
Example~ 1-5 Glucose was collected from an adult hllm~n using an apparatus substantially similar to the apparatus shown in Figures 1 and 2. The device was attached to the stratum corneum of the skin on the patient's forearm, and the device's reservoir was initially filled with a sample consisting of 0.5 ml. of distilled deionized water via a hypodermic needle and syringe. The sample was withdrawn from the reservoir after five minutes and was replaced with a fresh sample of distilled deionized water at five minute intervals for a total of 30 minutes. The final sample r~m~; n~ in the reservoir for 30 minutes before being withdrawn and analyzed.
The withdrawn samples were analyzed using pulsed amperometric voltammetry. The results are shown wo gs/02357 2 1 6 ~ 3 ~ 3 PCT/US94/06684 in Table I, with the glucose concentrations expressed in micromoles.
TABLE I
5¦ Sample 1 ¦2 ¦ 3 ¦4 ¦5 0-5 min3.13~M 2.86~M 6.10~M 9.24,1lM 1.66~M
5-10 min 1.74 " 1.42 " 3.80 " 4.07 " 1.05 "
10-15 min 1.08 " 0.85 " 2.53 n 2.90 " 0.83 "
15-20 min 1.44 " 0.88 " 1.67 " 2.24 " 0.56 "
20-25 min 1.13 " 0.46 " 1.48 " 2.57 " 0.70 "
25-30 min 0.77 " 0.56 " 1.15 " 3.07 " 1.09 "
1530-60 min 1.91 " 1.46 " 3.35 " 13.5 " 1.20 "
Claims (22)
1. A noninvasive method of monitoring blood glucose across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the following steps:
placing a reservoir of a glucose collection medium adjacent the patient's skin; and analyzing the glucose collection medium to measure the amount of glucose collected.
placing a reservoir of a glucose collection medium adjacent the patient's skin; and analyzing the glucose collection medium to measure the amount of glucose collected.
2. The method of claim 1 wherein the glucose collecting medium comprises water.
3. The method of claim 1 wherein the reservoir has an open side facing the patient's skin so that the glucose collection medium is in direct contact with the patient's skin.
4. The method of claim 1 wherein the recervoir comprises a glucose transfer membrane disposed between the glucose collection medium and the patient's skin.
5. The method of claim 1 wherein the analyzing step comprises pulsed amperometric detection.
6. The method of claim 1 wherein the analyzing step is performed at the end of a predetermined time period in the range of 5 to 10 minutes.
7. The method of claim 6 wherein the glucose collecting medium consists essentially of water.
8. The method of claim 7 further comprising the step of removing the glucose collection medium from the reservoir before the analyzing step.
9. The method of claim 8 wherein the analyzing step comprises pulsed amperometric detection.
10. The method of claim 1 wherein the analyzing step comprises exposing an glucose-responsive enzyme to the glucose collection medium, the enzyme being in contact with an indicating electrode.
11. A noninvasive method of collecting glucose from a patient across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the steps of placing a reservoir of a glucose collection medium adjacent the patient's skin for a period of time and removing at least a portion of the glucose collection medium from the reservoir.
12. A noninvasive method of collecting glucose from a patient across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the steps of placing a reservoir of a glucose collection medium adjacent the patient's skin and exposing a glucose-responsive enzyme to the glucose collection medium, the glucose-responsive enzyme being in contact with an indicating electrode.
13. A glucose collection device comprising:
a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer;
means for preventing the removal of liquid or liquid vapor from the reservoir apart from any glucose in the liquid; and means for attaching the device to a patient so that glucose can travel across the patient' B skin.
a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer;
means for preventing the removal of liquid or liquid vapor from the reservoir apart from any glucose in the liquid; and means for attaching the device to a patient so that glucose can travel across the patient' B skin.
14. The device of claim 13 wherein the glucose collection medium comprises water.
15. The device of claim 13 wherein the means for attaching comprises adhesive.
16. The device of claim 13 further comprising means for extracting the glucose collection medium from the reservoir without detaching the device from the patient.
17. A glucose monitoring system comprising:
a glucose collection device comprising a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer and means for attaching the device to a patient so that glucose can travel across the patient's skin; and means for measuring the concentration of glucose within the glucose collection medium.
a glucose collection device comprising a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer and means for attaching the device to a patient so that glucose can travel across the patient's skin; and means for measuring the concentration of glucose within the glucose collection medium.
18. The glucose monitoring system of claim 17 wherein the means for measuring comprises a glucose-responsive enzyme in contact with the glucose collection medium, an indicating electrode in contact with the enzyme, a reference electrode in contact with the patient's skin, and an instrument in electrical contact with the indicating electrode and the reference electrode.
19. A glucose collection device comprising:
a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer, the glucose collection medium comprising water;
and means for attaching the device to a patient so that glucose can travel across the patient's skin.
a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer, the glucose collection medium comprising water;
and means for attaching the device to a patient so that glucose can travel across the patient's skin.
20. A glucose monitoring system comprising:
a reservoir containing a glucose collection medium consisting essentially of water without any permeability enhancer or sweat inducer;
a reservoir attachment mechanism; and means for measuring the concentration of glucose within the glucose collection medium.
a reservoir containing a glucose collection medium consisting essentially of water without any permeability enhancer or sweat inducer;
a reservoir attachment mechanism; and means for measuring the concentration of glucose within the glucose collection medium.
21. A noninvasive method of monitoring blood glucose across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the following steps:
placing a reservoir of a glucose collection medium adjacent the patient's skin;
preventing the removal of glucose collection medium from the reservoir apart from any glucose contained in the glucose collection medium; and analyzing the glucose collection medium to measure the amount of glucose collected.
placing a reservoir of a glucose collection medium adjacent the patient's skin;
preventing the removal of glucose collection medium from the reservoir apart from any glucose contained in the glucose collection medium; and analyzing the glucose collection medium to measure the amount of glucose collected.
22. The method of claim 21 wherein the preventing step comprises preventing any evaporation of liquid from the reservoir.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9297593A | 1993-07-16 | 1993-07-16 | |
US08/092,975 | 1993-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2167393A1 true CA2167393A1 (en) | 1995-01-26 |
Family
ID=22236062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2167393 Abandoned CA2167393A1 (en) | 1993-07-16 | 1994-06-14 | Noninvasive glucose monitor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0708615A4 (en) |
JP (1) | JPH09503924A (en) |
AU (1) | AU7107394A (en) |
CA (1) | CA2167393A1 (en) |
WO (1) | WO1995002357A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8224414B2 (en) | 2004-10-28 | 2012-07-17 | Echo Therapeutics, Inc. | System and method for analyte sampling and analysis with hydrogel |
US8287483B2 (en) | 1998-01-08 | 2012-10-16 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
US8870810B2 (en) | 1998-12-18 | 2014-10-28 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5890489A (en) * | 1996-04-23 | 1999-04-06 | Dermal Therapy (Barbados) Inc. | Method for non-invasive determination of glucose in body fluids |
US5954685A (en) * | 1996-05-24 | 1999-09-21 | Cygnus, Inc. | Electrochemical sensor with dual purpose electrode |
US6139718A (en) * | 1997-03-25 | 2000-10-31 | Cygnus, Inc. | Electrode with improved signal to noise ratio |
US6587705B1 (en) | 1998-03-13 | 2003-07-01 | Lynn Kim | Biosensor, iontophoretic sampling system, and methods of use thereof |
ATE258028T1 (en) | 1998-05-13 | 2004-02-15 | Cygnus Therapeutic Systems | SIGNAL PROCESSING FOR MEASURING PHYSIOLOGICAL ANALYTES |
WO1999058973A1 (en) | 1998-05-13 | 1999-11-18 | Cygnus, Inc. | Method and device for predicting physiological values |
DK1053043T3 (en) | 1998-05-13 | 2002-11-18 | Cygnus Therapeutic Systems | Collection units for transdermal sampling systems |
JP3600158B2 (en) | 1998-05-13 | 2004-12-08 | シグナス, インコーポレイテッド | Monitoring physiological analytes |
US6180416B1 (en) | 1998-09-30 | 2001-01-30 | Cygnus, Inc. | Method and device for predicting physiological values |
PT1102559E (en) | 1998-09-30 | 2003-10-31 | Cygnus Therapeutic Systems | METHOD AND DEVICE FOR PREPARING PHYSIOLOGICAL VALUES |
ATE231017T1 (en) | 1998-10-28 | 2003-02-15 | Cygnus Therapeutic Systems | TEST SET AND METHOD FOR QUALITY TESTING OF AN IONTOPHORETIC SAMPLING SYSTEM |
US6561978B1 (en) | 1999-02-12 | 2003-05-13 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
EP1064046A1 (en) | 1999-04-22 | 2001-01-03 | Cygnus, Inc. | Methods and devices for removing interfering species |
US6251083B1 (en) | 1999-09-07 | 2001-06-26 | Amira Medical | Interstitial fluid methods and devices for determination of an analyte in the body |
US7011630B2 (en) | 2001-06-22 | 2006-03-14 | Animas Technologies, Llc | Methods for computing rolling analyte measurement values, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7150975B2 (en) | 2002-08-19 | 2006-12-19 | Animas Technologies, Llc | Hydrogel composition for measuring glucose flux |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US7497940B2 (en) | 2003-09-02 | 2009-03-03 | Koji Sode | Glucose sensor and glucose level measuring apparatus |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
EP2239567B1 (en) | 2003-12-05 | 2015-09-02 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
EP3111832B1 (en) * | 2004-07-13 | 2023-12-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8989833B2 (en) | 2004-07-13 | 2015-03-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7640048B2 (en) | 2004-07-13 | 2009-12-29 | Dexcom, Inc. | Analyte sensor |
US8386027B2 (en) | 2007-04-27 | 2013-02-26 | Echo Therapeutics, Inc. | Skin permeation device for analyte sensing or transdermal drug delivery |
CN105380662B (en) | 2008-07-31 | 2018-06-12 | 希森美康株式会社 | For measuring the method, apparatus and collecting part of in vivo ingredient |
EP2345893B1 (en) | 2008-11-04 | 2016-05-04 | Panasonic Healthcare Holdings Co., Ltd. | Measurement device, measurement method, and program |
JP2010271259A (en) | 2009-05-25 | 2010-12-02 | Sysmex Corp | Method, device, cartridge and kit for analyzing biological component |
KR101666978B1 (en) | 2014-09-17 | 2016-10-24 | 주식회사 아이센스 | Apparatus and Method for measuring concentration of Whole Blood Samples Using the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK8601218A (en) * | 1984-07-18 | 1986-03-17 | ||
US5076273A (en) * | 1988-09-08 | 1991-12-31 | Sudor Partners | Method and apparatus for determination of chemical species in body fluid |
US5139023A (en) * | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
US5056521A (en) * | 1989-06-29 | 1991-10-15 | Health Craft International, Inc. | Method for monitoring glucose level |
US5050604A (en) * | 1989-10-16 | 1991-09-24 | Israel Reshef | Apparatus and method for monitoring the health condition of a subject |
US5140985A (en) * | 1989-12-11 | 1992-08-25 | Schroeder Jon M | Noninvasive blood glucose measuring device |
US5036861A (en) * | 1990-01-11 | 1991-08-06 | Sembrowich Walter L | Method and apparatus for non-invasively monitoring plasma glucose levels |
-
1994
- 1994-06-14 AU AU71073/94A patent/AU7107394A/en not_active Abandoned
- 1994-06-14 EP EP94920190A patent/EP0708615A4/en not_active Withdrawn
- 1994-06-14 JP JP7504544A patent/JPH09503924A/en active Pending
- 1994-06-14 CA CA 2167393 patent/CA2167393A1/en not_active Abandoned
- 1994-06-14 WO PCT/US1994/006684 patent/WO1995002357A1/en not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8287483B2 (en) | 1998-01-08 | 2012-10-16 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
US8870810B2 (en) | 1998-12-18 | 2014-10-28 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
US8224414B2 (en) | 2004-10-28 | 2012-07-17 | Echo Therapeutics, Inc. | System and method for analyte sampling and analysis with hydrogel |
Also Published As
Publication number | Publication date |
---|---|
WO1995002357A1 (en) | 1995-01-26 |
AU7107394A (en) | 1995-02-13 |
EP0708615A4 (en) | 1996-10-16 |
JPH09503924A (en) | 1997-04-22 |
EP0708615A1 (en) | 1996-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2167393A1 (en) | Noninvasive glucose monitor | |
CA2332112C (en) | Monitoring of physiological analytes | |
US7066884B2 (en) | System, method, and device for non-invasive body fluid sampling and analysis | |
EP0766578B1 (en) | Iontophoretic sampling device | |
US7725149B2 (en) | Devices, methods, and kits for non-invasive glucose measurement | |
US8046043B2 (en) | Extraction device, analyzer, extraction method, and analysis method | |
CA2654980A1 (en) | Patches, systems, and methods for non-invasive glucose measurement | |
WO2006050033A9 (en) | System and method for analyte sampling and analysis | |
KR20010067623A (en) | Noninvasive Glucose Extraction through Skin by Reverse Iontophoresis or Electroosmosis | |
KR20190014875A (en) | Invasive continuous glucose monitoring system applying reverse iontophoresis and continuous glucose monitoring method using thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |